No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Botanix Pharmaceuticals Limited, an Australian enterprise, is dedicated to the discovery and advancement of novel dermatological and antimicrobial therapeutic agents. The company's central mission involves pioneering innovative treatments for widespread skin conditions and various infections. Its robust developmental portfolio showcases several key assets: Sofpironium Bromide, which has successfully completed Phase 3 clinical studies for managing primary axillary hyperhidrosis; BTX 1503, a transdermal gel designed to tackle severe acne in both adults and teenagers, having concluded Phase II trials; BTX 1801, which has progressed through Phase IIb clinical investigations for infections caused by Staphylococcus aureus (including its methicillin-resistant variant); BTX 1702, currently undergoing Phase IIb clinical evaluation for papulopustular rosacea; and BTX 1204A, targeting atopic dermatitis. Established in 1984, Botanix Pharmaceuticals operates from its headquarters in Leederville, Australia.
www.botanixpharma.comNo one on the platform currently holds BOT.AX.
No tracked institution reports a position in BOT.AX as of their last filing.
No one on the platform has traded BOT.AX yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 496.2% | 38.0% | ||||
| Profit Margin % | -202.2% | -1095.5% | ||||
| Free Cash Flow Margin % | -187.2% | -1698.7% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $59M | +77.0% | $-0.01 | $-0.01–$-0.01 | — | 1 |
| 2028 | $112M | +90.6% | $0.01 | $0.01–$0.01 | — | 2 |
| 2029 | $85M | -24.4% | $0.03 | $0.03–$0.04 | — | 1 |
| 2030 | $48M | -43.5% | $0.00 | $0.00–$0.00 | — | 0 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 1 of the last 4 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-26 | $-0.01 | $-0.01 | +0.0% |
| 2026-02-27 | $-0.01 | $-0.02 | -69.0% |
| 2025-08-29 | $-0.01 | $-0.03 | -200.0% |
| 2025-02-24 | $0.00 | $-0.02 | -1800.0% |
| +3.99% |
| $1.2B |
| — |
| DXB.AXDimerix Limited | $0.23 | -2.08% | $141M | — |
| MVF.AXMonash IVF Group Limited | $0.76 | -3.82% | $294M | — |
Source: Financial Modeling Prep · peers by sector/industry
$BOT.AX will be a good little grower i think.
View on StockTwits ↗
$BOT.AX check out this interview https://ioprivate.ventures/io-private-interview-botanix-pharmaceuticals/
View on StockTwits ↗
$BOT.AX This company has great potential with its synthetic CBD research.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.